PTGX financials
Protagonist Therapeutics (PTGX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
PTGX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $46.02M | $44.79M | -$158.13M | -$130.15M | -2.05 |
| 2024 | $434.43M | $434.43M | $252.84M | $275.19M | 4.23 |
| 2023 | $60.00M | $60.00M | -$93.65M | -$78.95M | -1.39 |
| 2022 | $26.58M | $26.58M | -$131.37M | -$127.39M | -2.52 |
| 2021 | $27.36M | $27.36M | -$125.84M | -$125.55M | -2.65 |
| 2020 | $28.63M | $28.63M | -$64.52M | -$66.15M | -1.92 |
- PTGX revenue was $46.02M in fiscal 2025, net income -$130.15M.
Updated 2026-11-02 23:14 UTC